Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Pitavastatin, a representative statin-series anti-dyslipidemic drug, and Valsartan, a
representative ARB-series anti-hypertensive drug, have been authorized for use also in South
Korea. They have been tested in many countries and proved to be effective and safe. The
concurrence of dyslipidemia and hypertension has a higher rate, hence statin-series drugs and
antihypertensive drugs are simultaneously administered to such patients. The combined
administration of statin-series drugs and CCB-series drugs have.